<DOC>
	<DOCNO>NCT01369784</DOCNO>
	<brief_summary>The purpose study evaluate prognostic value clinical biological factor patient refractory/relapsed Diffuse Large B-Cell Lymphoma .</brief_summary>
	<brief_title>Prognostic Value Clinical Biological Factors Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>The main aim study compare prognostic value R-IPI diagnosis relapse , relate obtain response second line</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Age 18 &gt; year old Patients refractory/relapsed diffuse large Bcell lymphoma first line treatment rituximab , without transplantation . Patients must finish rescue treatment include rituximab Ability understand willingness sign write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Diffuse large B-cell Lymphoma</keyword>
	<keyword>R-IPI</keyword>
</DOC>